...
机译:抗GD2 mAb和vorinostat协同治疗神经母细胞瘤
Radboud Univ Nijmegen Med Ctr Radboud Inst Mol Life Sci Dept Tumor Immunol Nijmegen Netherlands;
Radboud Univ Nijmegen Med Ctr Radboud Inst Mol Life Sci Dept Tumor Immunol Nijmegen Netherlands;
Radboud Univ Nijmegen Med Ctr Radboud Inst Mol Life Sci Dept Tumor Immunol Nijmegen Netherlands;
Radboud Univ Nijmegen Med Ctr Radboud Inst Mol Life Sci Dept Tumor Immunol Nijmegen Netherlands;
Radboud Univ Nijmegen Med Ctr Radboud Inst Mol Life Sci Dept Tumor Immunol Nijmegen Netherlands;
Radboud Univ Nijmegen Med Ctr Radboud Inst Mol Life Sci Dept Tumor Immunol Nijmegen Netherlands;
Radboud Univ Nijmegen Med Ctr Radboud Inst Mol Life Sci Dept Tumor Immunol Nijmegen Netherlands;
EPIRUS Biopharmaceut Netherlands BV Utrecht Netherlands;
Radboud Univ Nijmegen Med Ctr Radboud Inst Mol Life Sci Dept Tumor Immunol Nijmegen Netherlands;
Radboud Univ Nijmegen Med Ctr Dept Pediat Oncol Nijmegen Netherlands;
Radboud Univ Nijmegen Med Ctr Radboud Inst Mol Life Sci Dept Tumor Immunol Nijmegen Netherlands;
Anti-gd2 mAb therapy; histone deacytelase inhibitor; immunotherapy; myeloid-derived suppressor cell; neuroblastoma;
机译:抗GD2 mAb和vorinostat协同治疗神经母细胞瘤
机译:抗GD2免疫疗法后治疗耐药神经母细胞瘤群体
机译:抗GD2免疫疗法治疗高危神经母细胞瘤的研究进展
机译:用短饱和素和vorinostat的组合靶向视黄酸受体α和胸腺素-β4损害神经母细胞瘤细胞的存活和迁移
机译:神经母细胞瘤的发病机制和治疗
机译:抗GD2 mAb和伏立诺他协同治疗神经母细胞瘤
机译:抗GD2 mAb和vorinostat协同治疗神经母细胞瘤